OTOBIOTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTOBIOTIC (OTOBIOTIC).
Otobiotic is a fixed-dose combination of ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial DNA replication inhibition and cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and reducing inflammatory mediators.
| Metabolism | Ciprofloxacin undergoes hepatic metabolism via CYP1A2 (minor pathway) and renal excretion (50-70% unchanged). Fluocinolone acetonide is metabolized in the liver via CYP3A4 and excreted in urine and feces. |
| Excretion | Renal elimination of unchanged drug: 60-80%; biliary/fecal elimination: 10-20%; the remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life: 2-3 hours in patients with normal renal function; prolonged to 24-48 hours in anuria. |
| Protein binding | Plasma protein binding: 10-20%, primarily to albumin. |
| Volume of Distribution | Volume of distribution: 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid; low tissue penetration. |
| Bioavailability | Otic administration: locally high concentrations with negligible systemic absorption (<5%); systemic bioavailability is not clinically relevant for otic route. |
| Onset of Action | Otic administration: onset of antibacterial effect within 30 minutes; peak concentrations in ear fluids at 1-2 hours. |
| Duration of Action | Duration of action: 8-12 hours after otic administration, corresponding to sustained drug levels above MIC for common pathogens. |
Adults and children: 3-4 drops into the affected ear twice daily for 7 days. Shake well before use.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Weight-based dosing not applicable; use age-based dosing: children (including infants) 3-4 drops twice daily for 7 days. |
| Geriatric use | No specific adjustment needed; follow adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OTOBIOTIC (OTOBIOTIC).
| Breastfeeding | Excreted in breast milk; risk of infant ototoxicity. M/P ratio unknown; avoid breastfeeding unless benefits outweigh risks. |
| Teratogenic Risk | First trimester: Cardiac and neural tube defects (ototoxic antibiotics). Second and third trimesters: Hearing loss, nephrotoxicity; avoid unless essential. |
| Fetal Monitoring | Audiometry, renal function tests, drug serum levels, fetal ultrasound. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ciprofloxacin, any fluoroquinolone, or fluocinolone acetonide","Viral infections of the external ear (e.g., herpes simplex, varicella-zoster)","Fungal infections of the external ear"]
| Precautions | ["Not for ophthalmic use or injection","Hypersensitivity reactions including anaphylaxis","Prolonged use may result in fungal or bacterial superinfection","Perforation of tympanic membrane: use with caution in patients with suspected or known perforation","Corticosteroid withdrawal symptoms with abrupt discontinuation after prolonged use"] |
Loading safety data…
| Fertility Effects | May impair spermatogenesis; no evidence of female fertility effects. |